CurveBeam AI (CVB) Stock Overview
Engages in the development and manufacture of point-of care specialized weight bearing medical imaging equipment in Europe, North America, and Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
CVB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
CurveBeam AI Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.058 |
| 52 Week High | AU$0.17 |
| 52 Week Low | AU$0.045 |
| Beta | 2.01 |
| 1 Month Change | -15.94% |
| 3 Month Change | -27.50% |
| 1 Year Change | -35.56% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -82.94% |
Recent News & Updates
Recent updates
FDA Clearance And AI Advances Will Unlock Future Markets
As key valuation metrics such as the Future P/E and Discount Rate for CurveBeam AI showed only marginal shifts, the analyst consensus price target was maintained at A$0.15. What's in the News Auditor PricewaterhouseCoopers LLP expressed substantial doubt about CurveBeam AI's ability to continue as a going concern in the latest annual filing.Does CurveBeam AI (ASX:CVB) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
HiRise Orders And Australasian Expansion Will Fuel Market Success
Strong HiRise demand, expanded agreements, and protocol validation are set to drive revenue and sales growth, boosting future earnings.CurveBeam AI (ASX:CVB) Is Making Moderate Use Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Is CurveBeam AI (ASX:CVB) Weighed On By Its Debt Load?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Shareholder Returns
| CVB | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | -1.7% | -0.8% | -1.4% |
| 1Y | -35.6% | -45.8% | 3.0% |
Return vs Industry: CVB exceeded the Australian Medical Equipment industry which returned -46.3% over the past year.
Return vs Market: CVB underperformed the Australian Market which returned 3.7% over the past year.
Price Volatility
| CVB volatility | |
|---|---|
| CVB Average Weekly Movement | 11.4% |
| Medical Equipment Industry Average Movement | 10.5% |
| Market Average Movement | 10.3% |
| 10% most volatile stocks in AU Market | 17.4% |
| 10% least volatile stocks in AU Market | 4.4% |
Stable Share Price: CVB has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: CVB's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | n/a | Greg Brown | curvebeamai.com |
CurveBeam AI Limited engages in the development and manufacture of point-of care specialized weight bearing medical imaging equipment in Europe, North America, and Australia. The company offers HiRise for bilateral weight bearing CT imaging; LineUP, a bilateral, weight bearing CT imaging of the knees and lower extremities for orthpedic practices; pedCAT Premium and pedCAT for imaging of the foot and ankle; InReach, a point-of-care extremity CT imaging which assess the distal extremities with 3D clarity at a fraction of the dose; and CubeVue Software visualization tools. It also provides software CurveBeam AI Autometrics for automatically segment foot and ankle datasets; Axiometrics, provides a semi-automatic measurement of the axes of rotation of the hip, femur, knee, and ankle; and TALAS, a measurement tool that semi-automatically calculate hindfoot alignment based on reproducible three-dimensional anatomical landmarks.
CurveBeam AI Limited Fundamentals Summary
| CVB fundamental statistics | |
|---|---|
| Market cap | AU$27.71m |
| Earnings (TTM) | -AU$16.17m |
| Revenue (TTM) | AU$12.15m |
Is CVB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CVB income statement (TTM) | |
|---|---|
| Revenue | AU$12.15m |
| Cost of Revenue | AU$7.08m |
| Gross Profit | AU$5.07m |
| Other Expenses | AU$21.24m |
| Earnings | -AU$16.17m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.034 |
| Gross Margin | 41.75% |
| Net Profit Margin | -133.05% |
| Debt/Equity Ratio | 42.4% |
How did CVB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/15 08:25 |
| End of Day Share Price | 2026/05/15 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CurveBeam AI Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | Bell Potter |
| null null | Lodge Partners Pty Ltd. |